“…17,29,31,33,50,[53][54][55][56][57][58][59][60][61][62][63][64][65][66][67][68][69] The expression of UGTs is repressed in certain tumour types relative to their normal tissue counterparts, but remarkably enhanced in other cancers, such as those of the prostate, pancreas, lung, endometrium and in CLL, indicating diverse patterns of regulation of UGT expression in tumours. 17,29,31,33,50,[53][54][55][56][57][58][59][60][61][62][63][64][65][66][67][68][69] These perturbed levels of UGTs are consistent with altered metabolic functions in tumours and suggest that UGTs might influence cancer progression, independent of exposure to therapeutic drugs (Table 1). Notably, in recent reports investigating metabolic perturbations present in the transcriptome and metabolome of multiple tumour types, 7...…”